Holen Sie sich die Stockscreener-App
0.2351
0.17%
-0.0004
Vorhandelsmarkt:
.24
0.0049
+2.08%
Schlusskurs vom Vortag:
$0.2355
Offen:
$0.236
24-Stunden-Volumen:
1.40M
Relative Volume:
0.25
Marktkapitalisierung:
$10.21M
Einnahmen:
$40,400
Nettoeinkommen (Verlust:
$-9.18M
KGV:
-0.8759
EPS:
-0.2684
Netto-Cashflow:
$-5.78M
1W Leistung:
+1.42%
1M Leistung:
-30.44%
6M Leistung:
-79.56%
1J Leistung:
-74.99%
1-Tages-Spanne:
$0.234
$0.2476
1-Wochen-Bereich:
$0.2141
$0.254
52-Wochen-Spanne:
$0.1721
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Firmenname
Jupiter Neurosciences Inc
Sektor
Branche
Telefon
(561) 406-6154
Adresse
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.2351 | 10.23M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO - Yahoo Finance
Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: Narrower-than-expected loss highlights clinical pipeline progress - newsline.com
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
JUNS Q4 2025 Earnings: Narrower Loss Per Share Surpasses Estimates Amid No Revenue - newsline.com
JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN
Jupiter stock soars after $100 million ALA-002 licensing deal - MSN
Jupiter Neurosciences (JUNS) proposes 5.25M-plan increase and 1:10–1:100 reverse split - Stock Titan
Jupiter Neurosciences regains Nasdaq compliance for minimum share price - MSN
JUNS SEC FilingsJUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan
Jupiter Neurosciences, Inc. Announces Amendment No. 3 to Executive Employment Agreement for Alison Silva – SEC 8-K Filing, Nasdaq Listed Emerging Growth Company 14151618 - Minichart
Jupiter Neurosciences Promotes Silva to COO and President - TipRanks
Jupiter Neurosciences appoints Alison Silva as COO and President, grants options to executives - TradingView
Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: Narrower Loss Beats Expectations, but Stock SlipsRevenue Warning Signal - newsline.com
Jupiter Neurosciences (JUNS) Slides 11.57% as Selling Pressure Tests Key Support Near $0.25Risk Reversal - newsline.com
Jupiter Neurosciences (JUNS) Plunges 11.6%, Testing Key Support at $0.25Factor Timing - The Legal Advocate
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - ACCESS Newswire
Jupiter Neurosciences (JUNS) Slips 11.57%: Testing Key Support at $0.25Reversal Setup Alerts - newsline.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Jupiter Neurosciences (JUNS) Gains 10% as Trading Volume Picks Up Near Key ResistanceConversion Trade - The Legal Advocate
Jupiter Neurosciences Jumps 13.5% as Speculative Interest Builds in Small-Cap BiotechIchimoku TK Cross - newsline.com
Jupiter Neurosciences Initiates Phase 2a RESET Trial Enrolling Parkinson’s Patients - geneonline.com
Jupiter Neurosciences says patient enrollment underway in phase 2a reset trial in Parkinson's disease - marketscreener.com
Jupiter Neurosciences Says Patient Enrollment Underway In Phase 2A Reset Trial In Parkinson's Disease - TradingView
Jupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL™ in Parkinson’s Disease - Quiver Quantitative
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease - GlobeNewswire
Jupiter Neurosciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Jupiter Neurosciences earnings missed, revenue fell short of estimates - Investing.com
Jupiter Neurosciences Inc. (JUNS) Extends Slide – Key Support Levels Under PressureSector ETF Flow - thelegaladvocate.com
Jupiter Neurosciences (JUNS) Slips 3.28% as Shares Test Critical Support at $0.22Put Call Ratio - newsline.com
JUNS Q4 2025 Earnings: Narrower Loss Surprises, Yet Stock Falls on Pre‑Revenue PathPopular Market Picks - Newser
Jupiter Neurosciences (JUNS) Q4 2025 Earnings: EPS Beat Masks Zero-Revenue Reality; Shares Slide 12%Free Signal Network - Newser
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Reflects Cost Control Efforts Despite No RevenuePerformance Review - The Legal Advocate
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance Sheet - Quiver Quantitative
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - marketscreener.com
What's going on in today's after hours session - ChartMill
Jupiter Neurosciences (JUNS) priced 7.14M-share direct offering at $0.28 - Stock Titan
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Jupiter Neurosciences Announces Registered Direct Equity Offering - TipRanks
Jupiter Neurosciences (NASDAQ: JUNS) files May 21, 2026 prospectus supplement - Stock Titan
Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $0.28 Per Share - TradingView
Jupiter Neurosciences (JUNS) raises $2.0M in registered direct stock sale - Stock Titan
Jupiter Neurosciences (JUNS) raises $2.0M via 7.14M-share placement - Stock Titan
JUNS Q4 2025 Earnings: Narrowed Loss Beats Estimates as Development Focus IntensifiesDividend Earnings Report - newsline.com
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale - TechStock²
Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002 - The National Law Review
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jupiter Neurosciences Inc-Aktie (JUNS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROSEN CHRISTER | CEO and Chairman |
Jul 01 '25 |
Buy |
1.02 |
3,600 |
3,667 |
11,078,892 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 30 '25 |
Buy |
1.03 |
950 |
978 |
112,027 |
| Silva Alison D. | Pres + Chief Business Officer |
Jun 27 '25 |
Buy |
1.03 |
850 |
877 |
111,077 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 30 '25 |
Buy |
1.02 |
7,650 |
7,810 |
11,075,292 |
| ROSEN CHRISTER | CEO and Chairman |
Jun 27 '25 |
Buy |
1.06 |
166 |
176 |
11,067,642 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):